Showing 1841-1850 of 5643 results for "".
- Smartlens Closes $6.1 Million Series A Financing to Advance miLens Devicehttps://modernod.com/news/smartlens-closes-61-million-series-a-financing-to-advance-milens/2481727/Smartlens has closed an oversubscribed $6.1 million Series A equity financing round to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal IOP. The miLens device is an electronics free soft contact lens that uses mi
- Study Uncovers Novel Synaptic Intricacies Inside the Retinahttps://modernod.com/news/study-uncovers-novel-synaptic-intricacies-inside-the-retina/2481687/A Northwestern Medicine study has uncovered novel cellular mechanisms within the retina, findings that researchers say could help advance the development of targeted therapeutics for diseases and conditions impacting vision. The findings were
- Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 For the Treatment of Dry Eye Disease in Japanhttps://modernod.com/news/senju-pharmaceutical-and-novaliq-enter-into-license-agreement-for-nov03-for-the-treatment-of-dry-eye-disease-in-japan/2481671/Senju Pharmaceutical and Novaliq have enteed into a license agreement for NOV03 (perfluorohexyloctane ophthalmic solution) for the treatment of dry eye disease in Japan. Financial terms of the deal were not disclosed. Senju Pharmaceutical acquires the rights in Japa
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy/2481648/EyePoint Pharmaceuticals announced it has completed enrollment in the phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential 9-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). “We are delighted to report the completion of enrollment in
- FDA Approves Bausch + Lomb and Novaliq's Miebo for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-approval-of-miebotm-perfluorohexyloctane-ophthalmic-solution-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481625/Bausch + Lomb announced on Thursday that the FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) for the treatment of the signs and symptoms of dry eye disease (DED). The comapnies say Miebo is the first and only FDA-approved treatment fo
- Delta Gamma Foundation Awards RestoringVision with Grant to Serve People in Need of Vision Services and Eyeglasses in the UShttps://modernod.com/news/delta-gamma-foundation-awards-restoringvision-with-grant-to-serve-people-in-need-of-vision-services-and-eyeglasses-in-the-us/2481609/RestoringVision, a global nonprofit, recently won its third Service for Sight grant from the Delta Gamma Foundation. The funding will support bringing vision services and eyeglasses to 270,000 low-income people in the United States, according to RestoringVision. The award supports
- Trefoil’s TTHX1114 Improves Rate of Visual Recovery After Descemet Stripping Only (DSO) in Phase 2 STORM Datahttps://modernod.com/news/trefoils-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs/2481605/Trefoil Therapeutics announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the ph
- Norlase Receives FDA 510(k) Clearance and CE Mark Approval For ECHO Green Pattern Laserhttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-approval-for-echo-green-pattern-laser/2481597/Norlase has received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator. ECHO is a portable scanning laser photocoagulator utilizing MEMS technology. The laser and scanner are completely integrated into a single delivery device that
- Lumibird Launches Tango Neo and UltraQ Reflex Neo Lasershttps://modernod.com/news/lumibird-launches-tango-neo-and-ultraq-reflex-neo-lasers/2481570/Following the launch of its flagship product, the Tango Reflex Neo, in December 2022, Lumibird Medical announced the launch of two additional variants within its premium Nd:YAG/SLT laser range—the UltraQ Reflex Neo and Tango Neo. A fully integrated Q-switched Nd:YAG lase
- Lenstar Myopia Now Includes New AMMC Framework by Prof. Dr. Hakan Kaymakhttps://modernod.com/news/lenstar-myopia-now-includes-new-ammc-framework-by-prof-dr-hakan-kaymak/2481558/Haag-Streit has announced that the Lenstar Myopia now includes the new AMMC framework by Prof. Dr. Hakan Kaymak. The new Age-Matched Myopia Control (AMMC) framework is designed to provide diagnostic support based on the eye’s axial growth for myopia m